NL-OMON25511招募中不适用
A single arm multicenter biomarker study determining the response to taxane-based chemotherapy in metastatic breast cancer (MBC) patients with ESR1 mutations in cellfree DNA: TAX-ESR1 study
Erasmus MC Cancer Institute, department of Medical Oncology0 个研究点目标入组 185 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- 入组人数
- 185
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
入选标准
- •Female metastatic breast cancer patients with ER-positive, HER2- negative primary tumors;
- •- Previous treatment with at least an aromatase inhibitor either in adjuvant and/or metastatic setting;
排除标准
- •- Previous chemotherapy for metastatic disease; completed within three years before inclusion
- •- Patients with locally advanced disease, primary not amendable for resection or
- •radiation therapy with curative intent;
研究者
相似试验
招募中
不适用
A single arm multicenter biomarker study determining the response to taxane-based chemotherapy in metastatic breast cancer (MBC) patients with ESR1 mutations in cell-free DNA: TAX-ESR1 study.Metastasis of breast cancer10006291NL-OMON46354Erasmus MC, Universitair Medisch Centrum Rotterdam175
招募中
不适用
A multicenter study for validation of biomarkers and observational study for immune regulatory mechanisms in Juvenile Dermatomyositisrheumatic muscle disease1000381610028302juvenile dermatomyositisNL-OMON50706niversitair Medisch Centrum Utrecht365
已完成
不适用
A Multicenter Study on Biomarker Development Utilizing AI Multiomics for Patients with Advanced Solid Malignant TumorsAdvanced Solid MalignanciesJPRN-UMIN000043899ational Cancer Center Hospital East2,768
进行中（未招募）
1 期
A study to treat adult patients with a medicine who suffer from a low amount of remaining blood cancer cells after chemotherapy.minimal residual disease (MRD) of B-precursor ALLMedDRA version: 14.1 Level: LLT Classification code 10000845 Term: Acute lymphoblastic leukemia System Organ Class: 100000004864EUCTR2010-018314-75-PLAmgen Research (Munich) GmbH130
进行中（未招募）
1 期
A confirmatory multicenter, single-arm study to assess the efficacy, safety, and tolerability of the BiTE® antibody blinatumomab in adult patients with minimal residual disease (MRD) of B-precursor acute lymphoblastic leukemia - MT103-203minimal residual disease (MRD) of B-precursor ALLMedDRA version: 12.1 Level: LLT Classification code 10000845 Term: Acute lymphoblastic leukemiaEUCTR2010-018314-75-FRMicromet AG130